Literature DB >> 31792961

Capsids of hepatitis B virus e antigen with authentic C termini are stabilized by electrostatic interactions.

Norman R Watts1, Ira W Palmer1, Elif Eren2, Alasdair C Steven2, Paul T Wingfield1.   

Abstract

The hepatitis B virus e antigen, an alternative transcript of the core gene, is a secreted protein that maintains viral persistence. The physiological form has extended C termini relative to Cp(-10)149, the construct used in many studies. To examine the role of the C termini, we expressed the constructs Cp(-10)151 and Cp(-10)154, which have additional arginine residues. Both constructs when treated with reductant formed capsids more efficiently than Cp(-10)149. These capsids were also substantially more stable, as measured by thermal denaturation and resistance to urea dissociation. Mutagenesis suggests that electrostatic interactions between the additional arginine residues and glutamate residues on adjacent subunits play a role in the extra stabilization. These findings have implications for the physiological role and biotechnological potential of this protein. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  HBeAg; conformational rearrangement; e antigen; encapsidation; furin cleavage; hepatitis B virus

Mesh:

Substances:

Year:  2019        PMID: 31792961      PMCID: PMC7337981          DOI: 10.1002/1873-3468.13706

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   3.864


  37 in total

1.  The crystal structure of the human hepatitis B virus capsid.

Authors:  S A Wynne; R A Crowther; A G Leslie
Journal:  Mol Cell       Date:  1999-06       Impact factor: 17.970

2.  Moving towards high-resolution descriptions of the molecular interactions and structural rearrangements of the human hepatitis B core protein.

Authors:  Stefan M V Freund; Christopher M Johnson; Agnes M Jaulent; Neil Ferguson
Journal:  J Mol Biol       Date:  2008-10-15       Impact factor: 5.469

3.  The hepatitis B virus precore protein is retrotransported from endoplasmic reticulum (ER) to cytosol through the ER-associated degradation pathway.

Authors:  Marion Duriez; Jean-Michel Rossignol; Delphine Sitterlin
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

4.  Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences.

Authors:  Fabienne Messageot; Samia Salhi; Patricia Eon; Jean-Michel Rossignol
Journal:  J Biol Chem       Date:  2002-11-01       Impact factor: 5.157

5.  Posttranscriptional regulation of hepatitis B virus replication by the precore protein.

Authors:  P P Scaglioni; M Melegari; J R Wands
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  Immunochemical structure of hepatitis B e antigen in the serum.

Authors:  K Takahashi; A Machida; G Funatsu; M Nomura; S Usuda; S Aoyagi; K Tachibana; H Miyamoto; M Imai; T Nakamura; Y Miyakawa; M Mayumi
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

7.  An intramolecular disulfide bridge between Cys-7 and Cys61 determines the structure of the secretory core gene product (e antigen) of hepatitis B virus.

Authors:  M Nassal; A Rieger
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme.

Authors:  Kiyoaki Ito; Kyun-Hwan Kim; Anna Suk-Fong Lok; Shuping Tong
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

Review 9.  Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application.

Authors:  Jianming Hu; Kuancheng Liu
Journal:  Viruses       Date:  2017-03-21       Impact factor: 5.048

10.  Direct Inhibition of Hepatitis B e Antigen by Core Protein Allosteric Modulator.

Authors:  Zhipeng Yan; Daitze Wu; Hui Hu; Jing Zeng; Xin Yu; Zhiheng Xu; Zheng Zhou; Xue Zhou; Guang Yang; John A T Young; Lu Gao
Journal:  Hepatology       Date:  2019-03-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.